The global impact of endoscopic ultrasound (EUS) regarding the survival of a pancreatic adenocarcinoma in a tertiary hospital

Journal of Gastrointestinal Cancer

Volumn 41, Issue 3, 2010, Pages 165-172

  Ulla Rocha, Jose Luis ^a,c   Alvarez Prechous, Angel ^b   Paz Esquete, Javier ^a   Alvarez, Carlos Alvarez ^a   Lopez Clemente, Pedro ^a   Dominguez Comesaña, Elias ^a   Vazquez Astray, Enrique ^a  

^a HOSPITAL MONTECELO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Department of Neurology   (Spain)

Author keywords

Endoscopic ultrasonography; Pancreatic adenocarcinoma; Survival

Indexed keywords

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EVALUATION; ENDOSCOPIC ECHOGRAPHY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL RATE; SURVIVAL TIME; TERTIARY HEALTH CARE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, PANCREATIC DUCTAL; ENDOSONOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 78149464488     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9136-1     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Warshaw AL, Fernandez-del-Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326(7):455-65.
3. Mendieta Zerón H, García Flores JR, Romero Prieto ML. Limitations in improving detection of pancreatic adenocarcinoma. Future Oncol. 2009;5(5):657-68.
4. Mishra G, Conway JD. Endoscopic ultrasound in the evaluation of radiologic abnormalities of the liver and biliary tree. Curr Gastroenterol Rep. 2009;11(2):150-4.
5. Mori H. New insight of pancreatic imaging: from "unexplored" to "explored". Abdom Imaging. 2008; in press
6. Woods TO. Standards for medical devices in MRI: present and future. J Magn Reson Imaging. 2007;26(5):1186-9.
7. Barugola G, Frulloni L, Salvia R, et al. Is CA 19-9 a screening marker? Dig Liver Dis. 2009;41(5):325-7.
8. Savides TJ. Endosonography: new developments. Curr Opin Gastroenterol. 2009;25:428-32.
9. Chen VK, Arquedas MR, Kilgore ML, et al. A cost-minimization analysis of alternative strategies in diagnosing pancreatic cancer. Am J Gastroenterol. 2004;99(11):2223-34.
10. Hines OJ, Reber HA. Pancreatic surgery. Curr Opin Gastroenterol. 2009;24:603-11.
11. Cho A, Yamamoto H, Nagata M, et al. A totally laparoscopic pylorus-preserving pancreaticoduodenectomy and reconstruction. Surg Today. 2009;39(4):359-62.
12. Fujisaki S, Takashima M, Sakurai K, et al. A case of successfully management of liver metastases of pancreatic carcinoma by hepatectomy and adjuvant chemotherapy. Gan To Kagaku Ryoho. 2008;35(12):2109-11.
13. Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-13.
14. Ng SS, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 2002;1(10):777-83.
15. Rivera F, López-Tarruella S, Vega-Villegas ME, et al. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35 (4):335-9.
16. Wong HH, Lemoine RR. Pancreatic cancer: molecular pathogenesis and new therapeutic agents. Nat Rev Gastroenterol Hepatol. 2009;6:412-22.
17. Morganti AG, Valentini V, Macchia G, et al. Adjuvant radiotherapy in resectable pancreatic carcinoma. Eur J Surg Oncol. 2002;28 (5):523-30.
18. Nakai Y, Isayama H, Kawabe T. et al. Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine. 2008;37:405-10.
19. Morriss-Stiff G, Hassn A, Young WT. Self-expanding metal stents for duodenal obstruction in advanced pancreatic adenocarcinoma. HPB (Oxf). 2008;10(2):134-7.
20. Cho YK, Shin JH, Oh SY. Significance of palliative gastrojejunostomy for unresectable pancreatic head carcinoma. Hepatogastroenterology. 2008;55(81):254-7.
21. Freitas D, Fernandes Gdos S, Hoff PM, et al. Medical management of pancreatic adenocarcinoma. Pancreatology. 2009;9 (3):223-32.
22. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-57.
23. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14(4):1320-6.
24. Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten year singleinstitution experience. Oncology. 2009;76(6):413-9.
25. Chang DK, Nguyen NQ, Merrett ND, et al. Role of endoscopic ultrasound in pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2009;3(3):293-303.
26. Malik S, Kaushik N, Khalid A, et al. EUS yield in evaluating biliary dilatation in patients with normal serum liver enzymes. Dig Dis Sci. 2007;52(2):508-12.
27. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol. 2007;34(4):284-94. Review.
28. Fujita N, Noda Y, Kobayashi G, et al. Endoscopic approach to early diagnosis of pancreatic cancer. Pancreas. 2004;28(3):279-81.
29. Ikeda S, Maeshiro K, Ryu S, et al. Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients. Pancreas. 2009;38(4): e102-13.
30. Mansfield SD, Scott J, Oppong K, et al. Comparison of multislice computed tomography and endoscopic ultrasonography with operative and histological findings in suspected pancreatic and periampullary malignancy. Br J Surg. 2008;95(12):1512-20.
31. Linder S, Boström L, Nilsson B. Pancreatic carcinoma incidence and survival in Sweden in 1980-2000: a population-based study of 16,758 hospitalized patients with special reference to different therapies. Eur J Surg Oncol. 2007;33(5):616-22.
32. David M, Lepage C, Jouve JL, et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer. 2009;101 (2):215-8.
33. Artinyan A, Soriano PA, Prendergast C, et al. The anatomical location of pancreatic cancer is a prognostic factor for survival. HPB (Oxf). 2008;10(5):371-6.
34. Tseng JF, Pisters PW, Lee JE, et al. The learning curve in pancreatic surgery. Surgery. 2007;141(5):694-701.
35. Ross WA, Wasan SM, Evans DB, et al. Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed malignancy. Gastrointest Endosc. 2008;68(3): 461-6.
36. Ayaru L, Kurzawinski TL, Shankar A, et al. Complications and diagnostic difficulties arising from biliary self-expanding metal stent insertion before definitive histological diagnosis. J Gastroenterol Hepatol. 2008;23(2):315-20.
37. Westgaard A, Schjølberg AR, Cvancarova M, et al. Differentiation markers in pancreatic head adenocarcinoma: MUC 1 and MUC4 expression indicates poor prognosis in pancreaticobiliary differentiated tumours. Histopathology. 2009;54(3):337-47.
38. Greenhalf W, Grocock C, Harcus M, et al. Screening of high-risk families for pancreatic cancer. Pancreatology. 2009;9:215-22.
39. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104: 2175-81.
40. Lee YT, Lai AC, Hui H, et al. EUS in the management of uninvestigated dyspepsia. Gastrointest Endosc. 2002;56(6):842-8.